Cargando…
Portraying Immunity to Sars-Cov-2 after mRNA-Vaccination in Patients with Multiple Myeloma
Autores principales: | Enssle, Julius Christoph, Moter, Alina, Campe, Julia, Gessner, Alec, Yu, Ika Weijia, Wolf, Sebastian, Steffen, Björn, Serve, Hubert, Bremm, Melanie, Huenecke, Sabine, Lohoff, Michael, Vehreschild, Maria, Rabenau, Holger F., Widera, Marek, Ciesek, Sandra, Rieger, Michael A, Imkeller, Katharina, Metzler, Ivana von, Ullrich, Evelyn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology. Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665226/ http://dx.doi.org/10.1182/blood-2022-165871 |
Ejemplares similares
-
PB2070: IMMUNE RESPONSES AFTER SARS-COV-2 MRNA-VACCINATION AND INFECTION AT SINGLE CELL RESOLUTION IN PATIENTS WITH MULTIPLE MYELOMA
por: Enssle, Julius C., et al.
Publicado: (2023) -
Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma
por: Enssle, Julius C., et al.
Publicado: (2022) -
COVID-19 in multiple-myeloma patients: cellular and humoral immunity against SARS-CoV-2 in a short- and long-term view
por: von Metzler, Ivana, et al.
Publicado: (2021) -
Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma
por: Enßle, Julius C., et al.
Publicado: (2022) -
Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study
por: Kohmer, Niko, et al.
Publicado: (2023)